Rocket One Inc. Common Stock (NASDAQ:RKTO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a strong sell rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Rocket One Inc. Common Stock has a consensus rating of “Hold” and an average price target of $5.00.

Rocket One Inc. Common Stock Price Performance

RKTO stock opened at $0.50 on Friday. Rocket One Inc. Common Stock has a twelve month low of $0.48 and a twelve month high of $2.45. The company’s 50 day moving average is $0.70 and its two-hundred day moving average is $0.83.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last issued its earnings results on Friday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

Institutional Trading of Rocket One Inc. Common Stock

An institutional investor recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC boosted its stake in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,000 shares of the company’s stock after acquiring an additional 19,500 shares during the quarter. Lido Advisors LLC owned about 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.08% of the company’s stock.

Rocket One Inc. Common Stock Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.